logo
Plus   Neg
Share
Email

Kohl's Slashes FY19 Adj. EPS Guidance - Quick Facts

While reporting financial results for the third quarter on Tuesday, retailer Kohl's Corp. (KSS) slashed its adjusted earnings guidance for the full-year 2019. For the third quarter, the company reported that comparable sales increased 0.4 percent.

For fiscal 2019, the company slashed its adjusted earnings guidance to a range of $4.75 to $4.95 from the prior guidance range of $5.15 to $5.45 per share.

The current guidance excludes $0.22 per share related to the extinguishment of debt and impairments, store closing and other costs recognized in the first nine months of 2019.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $5.19 per share for the year. Analysts' estimates typically exclude special items.

Last week, Kohl's Board of Directors declared a quarterly cash dividend on the Company's common stock of $0.67 per share, payable on December 24, 2019 to shareholders of record at the close of business on December 11, 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
eBay Inc. (EBAY) Wednesday reported a fourth-quarter profit that trumped Wall Street analysts' estimates, as did revenues. However, shares of the company slipped over 5% after the company issued a weak outlook for the first quarter. eBay's fourth-quarter profit dropped to $558 million or $0.69 per... Apple Inc. (AAPL) Wednesday reported a first-quarter profit that trumped Wall Street estimates, as the iPhone maker reported its "highest quarterly revenue ever" driven by strong demand for its iPhone 11 and 11 Pro models during the holiday season. The tech giant also issued a strong revenue outlook... New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry.
Follow RTT
>